β2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats

Anna Klukovits, Eszter Ducza, I. Földesi, G. Falkay

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The objective of this study was to disclose an interaction between β2-adrenergic (β2-ARs) and oxytocin (OT) receptors (OTRs) in the late-pregnant rat uterus. We investigated the level of uterine OTR mRNA expression after the administration of β2-AR agonists fenoterol and hexoprenaline to rats from day 18 to 22 of pregnancy, and also tested the effect of fenoterol on uterine explants. Hexoprenaline induced a maximum 24% increase of OTR mRNA. Fenoterol in vivo elicited a maximum 125% increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA. In fenoterol-treated rats the maximal contractility increasing effect of OT on isolated uterine rings was significantly higher than in intact term pregnant rats, but the EC50 values were not statistically different. It was concluded that the enhanced expression of OTR mRNA induced by β2-agonists in the late-pregnant rat uterus may be a possible drawback to effective therapy of preterm uterine contractions with β2-agonists.

Original languageEnglish
Pages (from-to)60-65
Number of pages6
JournalMolecular Reproduction and Development
Volume69
Issue number1
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Oxytocin Receptors
Fenoterol
Hexoprenaline
Messenger RNA
Uterus
Uterine Contraction
Adrenergic Agonists
Oxytocin
Adrenergic Receptors
Pregnancy

Keywords

  • β-adrenergic receptor
  • Oxytocin receptor
  • Preterm birth
  • Rat
  • Upregulation

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology
  • Cell Biology

Cite this

β2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats. / Klukovits, Anna; Ducza, Eszter; Földesi, I.; Falkay, G.

In: Molecular Reproduction and Development, Vol. 69, No. 1, 09.2004, p. 60-65.

Research output: Contribution to journalArticle

@article{d16a366736894ec28663864b787abb69,
title = "β2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats",
abstract = "The objective of this study was to disclose an interaction between β2-adrenergic (β2-ARs) and oxytocin (OT) receptors (OTRs) in the late-pregnant rat uterus. We investigated the level of uterine OTR mRNA expression after the administration of β2-AR agonists fenoterol and hexoprenaline to rats from day 18 to 22 of pregnancy, and also tested the effect of fenoterol on uterine explants. Hexoprenaline induced a maximum 24{\%} increase of OTR mRNA. Fenoterol in vivo elicited a maximum 125{\%} increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA. In fenoterol-treated rats the maximal contractility increasing effect of OT on isolated uterine rings was significantly higher than in intact term pregnant rats, but the EC50 values were not statistically different. It was concluded that the enhanced expression of OTR mRNA induced by β2-agonists in the late-pregnant rat uterus may be a possible drawback to effective therapy of preterm uterine contractions with β2-agonists.",
keywords = "β-adrenergic receptor, Oxytocin receptor, Preterm birth, Rat, Upregulation",
author = "Anna Klukovits and Eszter Ducza and I. F{\"o}ldesi and G. Falkay",
year = "2004",
month = "9",
doi = "10.1002/mrd.20158",
language = "English",
volume = "69",
pages = "60--65",
journal = "Molecular Reproduction and Development",
issn = "1040-452X",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - β2-agonist treatment enhances uterine oxytocin receptor mRNA expression in pregnant rats

AU - Klukovits, Anna

AU - Ducza, Eszter

AU - Földesi, I.

AU - Falkay, G.

PY - 2004/9

Y1 - 2004/9

N2 - The objective of this study was to disclose an interaction between β2-adrenergic (β2-ARs) and oxytocin (OT) receptors (OTRs) in the late-pregnant rat uterus. We investigated the level of uterine OTR mRNA expression after the administration of β2-AR agonists fenoterol and hexoprenaline to rats from day 18 to 22 of pregnancy, and also tested the effect of fenoterol on uterine explants. Hexoprenaline induced a maximum 24% increase of OTR mRNA. Fenoterol in vivo elicited a maximum 125% increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA. In fenoterol-treated rats the maximal contractility increasing effect of OT on isolated uterine rings was significantly higher than in intact term pregnant rats, but the EC50 values were not statistically different. It was concluded that the enhanced expression of OTR mRNA induced by β2-agonists in the late-pregnant rat uterus may be a possible drawback to effective therapy of preterm uterine contractions with β2-agonists.

AB - The objective of this study was to disclose an interaction between β2-adrenergic (β2-ARs) and oxytocin (OT) receptors (OTRs) in the late-pregnant rat uterus. We investigated the level of uterine OTR mRNA expression after the administration of β2-AR agonists fenoterol and hexoprenaline to rats from day 18 to 22 of pregnancy, and also tested the effect of fenoterol on uterine explants. Hexoprenaline induced a maximum 24% increase of OTR mRNA. Fenoterol in vivo elicited a maximum 125% increase of OTR mRNA, in vitro produced a maximum fourfold increase in OTR mRNA. In fenoterol-treated rats the maximal contractility increasing effect of OT on isolated uterine rings was significantly higher than in intact term pregnant rats, but the EC50 values were not statistically different. It was concluded that the enhanced expression of OTR mRNA induced by β2-agonists in the late-pregnant rat uterus may be a possible drawback to effective therapy of preterm uterine contractions with β2-agonists.

KW - β-adrenergic receptor

KW - Oxytocin receptor

KW - Preterm birth

KW - Rat

KW - Upregulation

UR - http://www.scopus.com/inward/record.url?scp=3543081096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543081096&partnerID=8YFLogxK

U2 - 10.1002/mrd.20158

DO - 10.1002/mrd.20158

M3 - Article

C2 - 15278905

AN - SCOPUS:3543081096

VL - 69

SP - 60

EP - 65

JO - Molecular Reproduction and Development

JF - Molecular Reproduction and Development

SN - 1040-452X

IS - 1

ER -